AR086676A1 - Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa - Google Patents

Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa

Info

Publication number
AR086676A1
AR086676A1 ARP120101983A ARP120101983A AR086676A1 AR 086676 A1 AR086676 A1 AR 086676A1 AR P120101983 A ARP120101983 A AR P120101983A AR P120101983 A ARP120101983 A AR P120101983A AR 086676 A1 AR086676 A1 AR 086676A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
optionally substituted
cycloalkyl
heterocycloalkyl
Prior art date
Application number
ARP120101983A
Other languages
English (en)
Inventor
Elisabetta Armani
Gabriele Amari
Laura Carzaniga
Carmelida Capaldi
Oriana Esposito
Gino Villetti
Fanti Renato De
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR086676A1 publication Critical patent/AR086676A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Composiciones farmacéuticas, proceso para preparar los compuestos, uso terapéutico para enfermedades del tracto respiratorio, dispositivo.Reivindicación 1: Un compuesto caracterizado porque es de fórmula general [1] donde: R1 se selecciona entre el grupo que consiste en: H; cicloalquil C3-7carbonilo; alquilo C1-6, opcionalmente sustituido con uno o más sustituyentes seleccionados entre cicloalquilo C3-7 o cicloalquenilo C5-7; haloalquilo C1-6; cicloalquilo C3-7; cicloalquenilo C5-7; alquenilo C2-6; y alquinilo C2-6; R2 se selecciona entre el grupo que consiste en: H; cicloalquil C3-7carbonilo; alquilo C1-6, opcionalmente sustituido con uno o más sustituyentes seleccionados entre cicloalquilo C3-7 o cicloalquenilo C5-7; haloalquilo C1-6; cicloalquilo C3-7; cicloalquenilo C5-7; alquenilo C2-6; y alquinilo C2-6; o, cuando R19 es distinto de hidrógeno, R2 forma junto con R19 un grupo de fórmula [2] como se define más adelante; o R1 y R2, junto con los átomos que los conectan, forman un anillo 2,2-difluoro-1,3-dioxolano de fórmula [3] fusionado a la porción fenilo que lleva los grupos -OR1 y -OR2, donde los asteriscos indican átomos de carbono compartidos con dicho anillo fenilo; R19 es hidrógeno o, de ser distinto de hidrógeno, forma junto con R2 un grupo de fórmula [2] donde los enlaces marcados con (1) y (2) indican los puntos de unión del grupo de fórmula [2] a los átomos que llevan los grupos R19 y R2 respectivamente, de manera que R2 y R19 junto con los átomos que los conectan forman un anillo de fórmula [4] que está fusionado a un anillo fenilo que lleva los grupos -OR2 y R19, donde los asteriscos indican átomos de carbono compartidos con dicho anillo fenilo; R3 es uno o más sustituyentes seleccionados en forma independiente entre el grupo que consiste en H, CN, NO2, CF3 y átomos de halógeno; Z es un grupo -(CH2)n- donde n es 0 ó 1; A es un heterocicloalquileno C3-7 monocíclico saturado; K se selecciona entre el grupo que consiste en: -(CH2)mC(O)R4 donde m puede ser 0 ó 1; -C(O)(CH2)jR4 donde j puede ser 1 ó 2; -SO2(CH2)pR4 donde p puede ser cero, 1 ó 2; -(CH2)ySO2R4 donde y puede ser 1 ó 2; -(CH2)zR4 donde z puede ser 1 ó 2; y -C(O)(CH2)2SO2R4; R4 es un sistema de anillos, que es un anillo monocíclico o bicíclico que puede ser saturado, parcialmente insaturado o totalmente insaturado, como por ejemplo arilo, cicloalquilo C3-8, heterocicloalquilo C3- o heteroarilo, donde el anillo está opcionalmente sustituido con uno o más grupos R5 que pueden ser iguales o diferentes, y que se seleccionan en forma independiente entre el grupo que consiste en: alquilo C1-6 opcionalmente sustituido con uno o más grupos seleccionados en forma independiente de la lista que consiste en: cicloalquilo C3-7, -OH y un grupo -NR18C(O)alquilo C1-4, donde R18 es hidrógeno o alquilo C1-4; heterocicloalquilo C3-7; heteroarilo de 5 ó 6 miembros el cual está opcionalmente sustituido con uno o dos grupos alquilo C1-4; haloalquilo C1-6; heterocicloalquil C3-7alquilo C1-4; - un grupo -OR6 donde R6 se selecciona entre el grupo que consiste en H; haloalquilo C1-6; un grupo -SO2R7, donde R7es alquilo C1-4; un grupo -C(O)R7 donde R7 es alquilo C1-4; alquilo C1-10 opcionalmente sustituido con uno o más cicloalquilo C3-7 o con un grupo -NR8R9 como se define más adelante; y cicloalquilo C3-7; un grupo -SR20 donde R20 se selecciona entre el grupo que consiste en H; haloalquilo C1-6; - un grupo -C(O)R7 donde R7 es alquilo C1-4; alquilo C1-10 opcionalmente sustituido con uno o más cicloalquilo C3-7 o con un grupo -NR8R9; y cicloalquilo C3-7; átomos de halógeno; CN; - NO2; NR8R9 donde R8 y R9 son iguales o diferentes y se seleccionan en forma independiente entre el grupo que consiste en: H; alquilen C1-4-NR13R14 donde R13 y R14 son iguales o diferentes y se seleccionan en forma independiente entre el grupo que consiste en: H y alquilo C1-6, que está opcionalmente sustituido con cicloalquilo C3-7 o heterocicloalquilo C3-7; o forman con el átomo de nitrógeno al cual están unidos un anillo heterocíclico C3-7 saturado o parcialmente saturado; alquilo C1-6, opcionalmente sustituido con cicloalquilo C3-7, heterocicloalquilo C3-7, un grupo -OH o alcoxilo C1-6; un grupo -SO2R15, donde R15 se selecciona entre el grupo que consiste en: alquilo C1-4 opcionalmente sustituido con cicloalquilo C3-7 o heterocicloalquilo C3-7; heterocicloalquilo C3-7; y fenilo opcionalmente sustituido con uno o más alquilo C1-6, halógeno o un grupo -OH; un grupo -C(O)R16, donde R16 se selecciona entre el grupo que consiste en: alquilo C1-6 opcionalmente sustituido con cicloalquilo C3-7 o heterocicloalquilo C3-7; heterocicloalquilo C3-7; fenilo opcionalmente sustituido con uno o más alquilo C1-6, halógeno o -OH; y un grupo -NH2; un grupo -C(O)OR17, donde R17 se selecciona entre el grupo que consiste en: alquilo C1-6 opcionalmente sustituido con cicloalquilo C3-7 o heterocicloalquilo C3-7; heterocicloalquilo C3-7; fenilo opcionalmente sustituido con uno o más alquilo C1-6, halógeno o -OH; y un grupo -NH2; o forman con el átomo de nitrógeno al cual están unidos un anillo heterocíclico saturado o parcialmente saturado, que está opcionalmente sustituido con uno o más alquilo C1-6 o grupos oxo; alquilen C1-4-NR8R9 como se ha definido; COR10 donde R10 es fenilo o alquilo C1-6; oxo; -SO2R11 donde R11 es alquilo C1-4, OH o NR8R9 donde R8 y R9 son como se definen precedentemente; -COOR12 donde R12 es H, alquilo C1-4 o alquilen C1-4-NR8R9 donde R8 y R9 son como se definen precedentemente; y -CONR8R9 donde R8 y R9 son como se definen precedentemente; donde los grupos R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19 y R20 pueden tener significados iguales o diferentes en cada caso, si se encuentran presentes en más que un grupo; derivados N-óxido sobre el anillo piridina, o sales farmacéuticamente aceptables, o solvatos del mismo.
ARP120101983A 2011-06-06 2012-06-05 Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa AR086676A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11168853 2011-06-06

Publications (1)

Publication Number Publication Date
AR086676A1 true AR086676A1 (es) 2014-01-15

Family

ID=46458441

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101983A AR086676A1 (es) 2011-06-06 2012-06-05 Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa

Country Status (15)

Country Link
US (3) US20130005716A1 (es)
EP (1) EP2718267B1 (es)
JP (1) JP2014518203A (es)
KR (1) KR20140028049A (es)
CN (2) CN106946848B (es)
AR (1) AR086676A1 (es)
AU (1) AU2012266514A1 (es)
BR (1) BR112013028959A2 (es)
CA (1) CA2838435A1 (es)
MX (1) MX2013013557A (es)
RU (1) RU2626956C2 (es)
SG (1) SG195319A1 (es)
UA (1) UA111198C2 (es)
WO (1) WO2012168226A1 (es)
ZA (1) ZA201309150B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
CN106890165A (zh) 2010-08-03 2017-06-27 奇斯药制品公司 包含磷酸二酯酶抑制剂的干粉制剂
WO2013045280A1 (en) 2011-09-26 2013-04-04 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
KR20150022789A (ko) 2012-06-04 2015-03-04 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
BR112015012949A2 (pt) 2012-12-05 2017-07-11 Chiesi Farm Spa composto, composição farmaceutica, uso de um composto, dispositivo inalatório e kit
TW201439089A (zh) 2012-12-05 2014-10-16 Chiesi Farma Spa 新穎化合物
TW201434817A (zh) 2012-12-05 2014-09-16 Chiesi Farma Spa 新穎化合物
ES2716142T3 (es) 2012-12-05 2019-06-10 Chiesi Farm Spa Derivados del alcohol de 1-fenil-2-piridinil alquilo como inhibidores de la fosfodiesterasa
US9326976B2 (en) 2014-06-05 2016-05-03 Chiesi Farmaceutici S.P.A. Carbamate derivatives
WO2016177849A1 (en) * 2015-05-07 2016-11-10 Chiesi Farmaceutici S.P.A. Aminoester derivatives
AR104822A1 (es) * 2015-06-01 2017-08-16 Chiesi Farm Spa Derivado de aminoésteres
AR104829A1 (es) * 2015-06-01 2017-08-16 Chiesi Farm Spa Derivados de aminoésteres
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
CN107094329B (zh) * 2017-05-03 2019-01-29 矽力杰半导体技术(杭州)有限公司 Led驱动电路
CN115466169B (zh) * 2021-06-10 2024-03-26 中国医学科学院药物研究所 取代邻苯二酚醚类化合物及其制备方法和应用
WO2023178378A1 (en) * 2022-03-21 2023-09-28 DMTC Limited Mip inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9304571A (es) 1992-07-28 1994-05-31 Rhone Poulenc Rorer Ltd Compuestos fanilicos ligados a un arilo o heteroarilo mediante un radical alifatico o un atomo heterogeneo que contiene un grupo eslabonador.
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
SE9903995D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New combination
AU2003252467A1 (en) 2002-07-03 2004-01-23 Kyowa Hakko Kogyo Co., Ltd. Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives
EP1634606A1 (en) 2003-03-31 2006-03-15 Kyowa Hakko Kogyo Co., Ltd. Drug for airway administration
CN101123970A (zh) * 2003-07-31 2008-02-13 埃匹吉尼斯医药有限公司 治疗哮喘或慢性阻塞性肺病的脱氢表雄酮或硫酸脱氢表雄酮与抗胆碱能支气管扩张剂的组合
US20090274676A1 (en) 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
CN101123971A (zh) 2003-07-31 2008-02-13 埃匹吉尼斯医药有限公司 治疗哮喘或慢性阻塞性肺病的脱氢表雄酮或硫酸脱氢表雄酮与pde-4抑制剂的组合
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
EP2044023B1 (en) 2006-07-14 2011-01-19 CHIESI FARMACEUTICI S.p.A. Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
JP2008174213A (ja) * 2006-12-20 2008-07-31 Nsk Ltd 舵角可変式ステアリング装置
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2110375A1 (en) 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
RU2578975C2 (ru) 2010-08-03 2016-03-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы
CN106890165A (zh) 2010-08-03 2017-06-27 奇斯药制品公司 包含磷酸二酯酶抑制剂的干粉制剂
WO2013045280A1 (en) 2011-09-26 2013-04-04 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
RU2617401C2 (ru) * 2011-10-21 2017-04-25 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстеразы
KR20150022789A (ko) 2012-06-04 2015-03-04 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
BR112015012949A2 (pt) * 2012-12-05 2017-07-11 Chiesi Farm Spa composto, composição farmaceutica, uso de um composto, dispositivo inalatório e kit

Also Published As

Publication number Publication date
US20130005716A1 (en) 2013-01-03
CN106946848B (zh) 2022-01-04
UA111198C2 (uk) 2016-04-11
WO2012168226A1 (en) 2012-12-13
EP2718267A1 (en) 2014-04-16
KR20140028049A (ko) 2014-03-07
US9931327B2 (en) 2018-04-03
AU2012266514A1 (en) 2014-01-09
CA2838435A1 (en) 2012-12-13
CN103562185A (zh) 2014-02-05
CN106946848A (zh) 2017-07-14
US20140057882A1 (en) 2014-02-27
SG195319A1 (en) 2013-12-30
US20160008338A1 (en) 2016-01-14
RU2013154117A (ru) 2015-06-10
ZA201309150B (en) 2015-03-25
JP2014518203A (ja) 2014-07-28
MX2013013557A (es) 2013-12-16
BR112013028959A2 (pt) 2016-08-30
EP2718267B1 (en) 2016-08-10
RU2626956C2 (ru) 2017-08-02

Similar Documents

Publication Publication Date Title
AR086676A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa
AR068057A1 (es) Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio.
AR086977A1 (es) Derivados heterociclicos nitrogenados utiles para el tratamiento del cancer y composiciones farmaceuticas que los contienen
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR062074A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
AR071300A1 (es) Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento
AR062503A1 (es) Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor.
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR072249A1 (es) Inhibidores de amida hidrolasa de acido graso. usos. metodos.
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR085283A1 (es) Antagonistas de hepcidina a base de sulfonaminoquinolina
AR084408A1 (es) Compuestos de purina y 7-deazapurina substituidos
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR092288A1 (es) Ligandos del receptor ep1
AR072162A1 (es) Compuestos de ester boronato y composiciones farmaceuticas de los mismos
AR053011A1 (es) Compuestos de heteroarilo como inhibidores del receptor p2y1, composiciones farmaceuticas que los contienen y su uso en la manufactura de un medicamento para el tratamiento de un trastorno tromboembolico
AR069510A1 (es) Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10
AR081932A1 (es) Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes
AR087288A1 (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a
AR078535A1 (es) Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
AR088014A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de la fosfodiesterasa
AR084152A1 (es) Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
AR065531A1 (es) Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure